SNX16

Across TCGA pan-cancer cohorts, SNX16 RNA differs between tumor and matched normal tissue in 8 of 18 cancer types tested, making tumor–normal expression one of SNX16’s most consistent transcriptional readouts.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where SNX16 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types SNX16 is over-expressed in tumor, although a few such as KICH show the opposite, repressed pattern.

LIHC, KIRP, and CHOL are the cancer types where SNX16 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in SNX16 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
LIHC	Male	II,III,IV	+0.775	<.001	9	view →
KIRP	All	II,III,IV	+0.650	.002	8	view →
CHOL	Male	All	+1.101	<.001	5	view →
HNSC	Female	IV	+0.973	.007	5	view →
LUSC	All	II,III,IV	+0.562	<.001	5	view →
KICH	All	All	−0.430	.003	4	view →
STAD	All	II,III,IV	+0.414	.045	2	view →
PRAD	All	All	+0.246	.025	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 8 strongest of 8 lineages.

SNX16–LIHC

Open the LIHC breakdown →